Vergelijking

Cetrorelix vs. Icatibant

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

120287-85-6

138614-30-9

Molecuulmassa

1431.06 g/mol

1304.52 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Cetrorelix

Cetrorelix competitively and immediately blocks the pituitary GnRH receptor, rapidly suppressing LH and FSH release — without the initial hormone surge ('flare') of GnRH agonists.

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Cetrorelix	Icatibant
Duitsland	Op recept	Op recept
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Cetrorelix

Volledige vermelding →

Icatibant

Volledige vermelding →

Frequently asked questions

What is the difference between Cetrorelix and Icatibant?: Cetrorelix is classified as "Onderzoek (overig)", while Icatibant is classified as "Onderzoek (overig)". Cetrorelix: Cetrorelix is a synthetic decapeptide and GnRH antagonist. It is used in assisted reproduction (IVF) to prevent a premature LH surge during controlled ovarian stimulation. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Cetrorelix or Icatibant?: The highest available evidence level is "Humane RCT" for Cetrorelix and "Humane RCT" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Cetrorelix and Icatibant in Germany and the United States?: Duitsland: Cetrorelix — Op recept, Icatibant — Op recept. Verenigde Staten: Cetrorelix — Op recept, Icatibant — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Cetrorelix

Icatibant

Duitsland

Op recept

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Cetrorelix and Icatibant?

Cetrorelix is classified as "Onderzoek (overig)", while Icatibant is classified as "Onderzoek (overig)". Cetrorelix: Cetrorelix is a synthetic decapeptide and GnRH antagonist. It is used in assisted reproduction (IVF) to prevent a premature LH surge during controlled ovarian stimulation. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Cetrorelix or Icatibant?

The highest available evidence level is "Humane RCT" for Cetrorelix and "Humane RCT" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Cetrorelix and Icatibant in Germany and the United States?

Duitsland: Cetrorelix — Op recept, Icatibant — Op recept. Verenigde Staten: Cetrorelix — Op recept, Icatibant — Op recept. These are factual summaries with source and review date on the individual pages.